Using the molecular classification of glioblastoma to inform personalized treatment
A Olar, KD Aldape - The Journal of pathology, 2014 - Wiley Online Library
Glioblastoma is the most common and most aggressive diffuse glioma, associated with short
survival and uniformly fatal outcome, irrespective of treatment. It is characterized by …
survival and uniformly fatal outcome, irrespective of treatment. It is characterized by …
Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments
S Kesari - Seminars in oncology, 2011 - Elsevier
Glioblastoma (GBM) is a highly malignant brain cancer characterized by uncontrolled
cellular proliferation, diffuse infiltration, a tendency for necrosis, significant angiogenesis …
cellular proliferation, diffuse infiltration, a tendency for necrosis, significant angiogenesis …
Molecular genetics of gliomas
Diffusely infiltrating gliomas are the most common primary brain tumors and include
astrocytomas, oligodendrogliomas, and oligoastrocytomas of grades II and III and …
astrocytomas, oligodendrogliomas, and oligoastrocytomas of grades II and III and …
Fusion radiomics features from conventional MRI predict MGMT promoter methylation status in lower grade gliomas
C Jiang, Z Kong, S Liu, S Feng, Y Zhang, R Zhu… - European journal of …, 2019 - Elsevier
Purpose The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT)
promoter has been proven to be a prognostic and predictive biomarker for lower grade …
promoter has been proven to be a prognostic and predictive biomarker for lower grade …
Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis
Gliomas are a large and diverse group of primary brain tumors that include those that are
diffusely infiltrative and others that are well-circumscribed and low grade. Diffuse gliomas …
diffusely infiltrative and others that are well-circumscribed and low grade. Diffuse gliomas …
Artificial intelligence in glioma imaging: challenges and advances
Primary brain tumors including gliomas continue to pose significant management
challenges to clinicians. While the presentation, the pathology, and the clinical course of …
challenges to clinicians. While the presentation, the pathology, and the clinical course of …
Beyond brooding on oncometabolic havoc in IDH-mutant gliomas and AML: current and future therapeutic strategies
Isocitrate dehydrogenases 1 and 2 (IDH1, 2), the key Krebs cycle enzymes that generate
NADPH reducing equivalents, undergo heterozygous mutations in> 70% of low-to mid …
NADPH reducing equivalents, undergo heterozygous mutations in> 70% of low-to mid …
A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival
The median survival time of patients with glioblastoma multiforme (GBM) is 12months, and
only 3–5% of patients survive longer than 3years. We performed histomorphological and …
only 3–5% of patients survive longer than 3years. We performed histomorphological and …
IDH mutations in human glioma
W Kim, LM Liau - Neurosurgery clinics of North America, 2012 - Elsevier
A novel mutation of isocitrate dehydrogenase-1 (IDH1) was recently found in a large
percentage of secondary human gliomas. Unlike previously discovered prognostic …
percentage of secondary human gliomas. Unlike previously discovered prognostic …
MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors
M Mellai, O Monzeglio, A Piazzi, V Caldera… - Journal of neuro …, 2012 - Springer
Abstract MGMT (O 6-methylguanine-DNA methyltransferase) promoter hypermethylation is a
helpful prognostic marker for chemotherapy of gliomas, although with some controversy for …
helpful prognostic marker for chemotherapy of gliomas, although with some controversy for …